Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma

WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
September 13, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe

Trial launch in Europe coincides with the Company’s upcoming presentation at the European Society for Medical Oncology Congress WILMETTE, Ill., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Monopar...
September 09, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Therapeutics to Present at Upcoming Investor Conferences in September

WILMETTE, Ill., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
August 12, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021Validive® Phase 2b/3 VOICE Trial on Track for Reaching Interim Analysis in H1 2022 WILMETTE, Ill., Aug. 12, 2021 ...
August 05, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
August 03, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

WILMETTE, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
July 12, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
June 24, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
June 03, 2021 09:19 ET | Source: Monopar Therapeutics Inc.

Monopar公布新候选药物MNPR-202，并与新加坡国立大学签订癌症临床前评估合作协议

伊利诺伊州威尔梅特, June 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（纳斯达克股票代码：MNPR）是一家临床阶段生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法。公司今日宣布，已与新加坡国立大学（NUS）下属新加坡癌症科学研究所（CSI...
June 03, 2021 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

WILMETTE, Ill., June 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...